Date | Time | Source | Headline | Symbol | Company |
05/31/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation | EU:SAN | Sanofi |
05/31/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation | EU:SAN | Sanofi |
05/30/2024 | 9:01AM | GlobeNewswire Inc. | Press Release: Sanofi completes acquisition of Inhibrx, Inc. | EU:SAN | Sanofi |
05/30/2024 | 9:01AM | GlobeNewswire Inc. | Press Release: Sanofi completes acquisition of Inhibrx, Inc. | EU:SAN | Sanofi |
05/30/2024 | 9:01AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc. | EU:SAN | Sanofi |
05/27/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation | EU:SAN | Sanofi |
05/27/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma | EU:SAN | Sanofi |
05/27/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma | EU:SAN | Sanofi |
05/21/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration | EU:SAN | Sanofi |
05/21/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration | EU:SAN | Sanofi |
05/21/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA | EU:SAN | Sanofi |
05/20/2024 | 4:54PM | GlobeNewswire Inc. | Sanofi: Information concerning the total number of voting rights and shares - April 2024 | EU:SAN | Sanofi |
05/20/2024 | 4:54PM | GlobeNewswire Inc. | Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024 | EU:SAN | Sanofi |
05/20/2024 | 2:15PM | GlobeNewswire Inc. | Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM | EU:SAN | Sanofi |
05/20/2024 | 2:15PM | GlobeNewswire Inc. | Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM | EU:SAN | Sanofi |
05/20/2024 | 2:15PM | GlobeNewswire Inc. | Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO | EU:SAN | Sanofi |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaire | EU:SAN | Sanofi |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty | EU:SAN | Sanofi |
05/13/2024 | 1:00AM | GlobeNewswire Inc. | Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) | EU:SAN | Sanofi |
05/10/2024 | 2:00AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 | EU:SAN | Sanofi |
05/10/2024 | 2:00AM | GlobeNewswire Inc. | Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines | EU:SAN | Sanofi |
05/10/2024 | 2:00AM | GlobeNewswire Inc. | Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines | EU:SAN | Sanofi |
05/02/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations | EU:SAN | Sanofi |
05/02/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations | EU:SAN | Sanofi |
04/30/2024 | 12:00PM | GlobeNewswire Inc. | Press Release: Annual General Meeting of April 30, 2024 | EU:SAN | Sanofi |
04/30/2024 | 12:00PM | GlobeNewswire Inc. | Press Release: Annual General Meeting of April 30, 2024 | EU:SAN | Sanofi |
04/30/2024 | 12:00PM | GlobeNewswire Inc. | Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 | EU:SAN | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements | EU:SAN | Sanofi |
04/25/2024 | 1:30AM | GlobeNewswire Inc. | Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance | EU:SAN | Sanofi |
04/23/2024 | 1:00AM | GlobeNewswire Inc. | Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia | EU:SAN | Sanofi |